- Home
- SEER vs LPTX Comparison
SEER vs LPTX Comparison
Compare SEER & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEER
- LPTX
- Stock Information
- Founded
- SEER 2017
- LPTX 2011
- Country
- SEER United States
- LPTX United States
- Employees
- SEER N/A
- LPTX N/A
- Industry
- SEER Medicinal Chemicals and Botanical Products
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SEER Health Care
- LPTX Health Care
- Exchange
- SEER Nasdaq
- LPTX Nasdaq
- Market Cap
- SEER 105.0M
- LPTX 111.0M
- IPO Year
- SEER 2020
- LPTX N/A
- Fundamental
- Price
- SEER $1.69
- LPTX $3.05
- Analyst Decision
- SEER Hold
- LPTX Strong Buy
- Analyst Count
- SEER 1
- LPTX 5
- Target Price
- SEER $3.00
- LPTX $10.40
- AVG Volume (30 Days)
- SEER 296.7K
- LPTX 88.3K
- Earning Date
- SEER 11-05-2024
- LPTX 11-11-2024
- Dividend Yield
- SEER N/A
- LPTX N/A
- EPS Growth
- SEER N/A
- LPTX N/A
- EPS
- SEER N/A
- LPTX N/A
- Revenue
- SEER $14,738,000.00
- LPTX N/A
- Revenue This Year
- SEER N/A
- LPTX N/A
- Revenue Next Year
- SEER $43.19
- LPTX N/A
- P/E Ratio
- SEER N/A
- LPTX N/A
- Revenue Growth
- SEER N/A
- LPTX N/A
- 52 Week Low
- SEER $1.46
- LPTX $1.24
- 52 Week High
- SEER $2.62
- LPTX $5.00
- Technical
- Relative Strength Index (RSI)
- SEER 53.32
- LPTX 63.89
- Support Level
- SEER $1.59
- LPTX $2.71
- Resistance Level
- SEER $1.73
- LPTX $2.88
- Average True Range (ATR)
- SEER 0.06
- LPTX 0.16
- MACD
- SEER 0.01
- LPTX -0.02
- Stochastic Oscillator
- SEER 71.43
- LPTX 90.15
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .